| Autor: |
Squires, H.Y., Poku, E., Bermejo, I., Cooper, K., Stevens, J., Hamilton, J., Wong, R., Denniston, A., Pearce, I., Quhill, F. |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| ISSN: |
1366-5278 |
| Popis: |
Background: Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a heterogeneous group of inflammatory eye disorders. Management includes local and systemic corticosteroids, immunosuppressants and biologic drugs. \ud \ud Objectives: To evaluate clinical and cost-effectiveness of subcutaneous adalimumab and dexamethasone intravitreal implant in adults with non-infectious intermediate, posterior or panuveitis.\ud \ud Methods: Nine electronic databases were searched to June 2016. A Markov model was developed to assess cost-effectiveness of dexamethasone and adalimumab, each compared with current practice, from an NHS and PSS perspective over a lifetime horizon, parameterised with published evidence. Costs and benefits were discounted at 3.5%. Substantial sensitivity analyses were undertaken. \ud \ud Results: Two studies (VISUAL I, active uveitis; and VISUAL II, inactive uveitis) compared adalimumab against placebo, plus limited standard care in both arms. Time to treatment failure (reduced visual acuity, intraocular inflammation, new vascular lesions) was longer for adalimumab than placebo, with hazard ratio 0.50 (95% CI 0.36 to 0.70, p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
